Botox is the go-to beauty treatment for everything from fine lines to excessive sweating. Its popularity continues to grow over the years as even young women without a single line on their faces are turning to the toxin as a preventative measure against skin aging. But despite its widespread use, many people question the safety of this injectable as side effects have been reported in the aftermath of some treatments. Thus, experts have gone back to the drawing board to develop what is said to be better versions of the original formula.
The new and improved botulinum toxin products, which have been developed in Asia, promises to be better and more effective than the toxins that are being used nowadays. But are these new products safer, and will they reduce the risks of side effects? Here’s what you need to know about these up-and-coming injectables.
The Science Behind The Effects Of Botox
Botox aficionados know that the effect of the toxin wears off after a few months. As a result, the fine lines and wrinkles that have been temporarily smoothed out will eventually show up on the face again. According to the Korea Biomedical Review, the effects of the toxin decreases due to body absorption and other factors. This is why follow up treatments are required.
As of the moment, all locally produced botulinum toxins in the market are 900kDa products, meaning that the formula is made up of a mixture of neurotoxin and complex protein. It takes only 150kDa of the 900kDa to bring out the toxin effect, and the rest is made up of complex protein. Experts believe that reducing the complex protein in the formula and leaving only pure neurotoxin may be the way to prevent patients from developing a resistance to the toxin, and may also omit side effects.
One South Korean company is leading the pack when it comes to wrinkle prevention innovations. Medytox, a company that develops and manufactures botulinum toxin, hyaluronic acid filler, and other medical devices has come up with an anti-wrinkle filler called Coretox. An official from the company told The Investor that Coretox, which is Medytox’s third toxin product, is safer than other formulas available in the market due to the complete absence of complex proteins, meaning that it is made up of pure 130kDa neurotoxin. It has received approval from the Korean Ministry of Food and Drug in June 2016. Medytox is also set to release a new botulinum toxin called Neuronox in China, where it is expected to win a license in the second quarter of 2019.
Though Medytox is undoubtedly one of the most innovative developers of the injectable, another company is gaining traction as it has recently entered the Canadian market. Daewoong Pharmaceutical, which is also based in South Korea, has recently received sales approval for Nabota, its BTX product to treat forehead wrinkles. Nabota is Daewoong’s first product to acquire sales approval from an advanced country and is 6expected to gain approval from the US Food and Drug Administration by February 2019.
With these up-and-coming products giving Dysport, Xeomin, and Allergan’s Botox a run for their money, it is expected that more people will be open to getting shots of these toxins in the quest for younger-looking skin and a wrinkle-free visage. As Medytox and Daewoong are making headway towards the US and European markets, these companies have the potential to become the go-to for anti-wrinkle treatments all over the world.
Resources & Further Reading:
1. This Is the Age You Should Start Preventative Botox, According to Dermatologists, Allure, https://www.allure.com/story/preventative-botox-age-dermatologists
2. Competition heats up among Korean Botox makers to develop ‘kDa’, Korea Biomedical Review, http://www.koreabiomed.com/news/articleView.html?idxno=3909
3. Medytox plans to launch protein-free botulinum toxin product this year, The Investor, http://www.theinvestor.co.kr/view.php?ud=20170317000816
4. Medy Tox : Medytox in final stage to sell facial filler in China, MarketScreener, https://www.marketscreener.com/MEDY-TOX-INC-6500355/news/Medy-Tox-Medytox-in-final-stage-to-sell-facial-filler-in-China-25996078/
5. Health Canada approves Daewoong’s BTX, BioSpectrum Asia, https://www.biospectrumasia.com/news/51/11529/health-canada-approves-daewoongs-btx.html
6. Daewoong’s Nabota likely to gain FDA approval in Feb., The Investor, http://www.theinvestor.co.kr/view.php?ud=20180803000580